![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LRRIQ1 |
Gene summary for LRRIQ1 |
![]() |
Gene information | Species | Human | Gene symbol | LRRIQ1 | Gene ID | 84125 |
Gene name | leucine rich repeats and IQ motif containing 1 | |
Gene Alias | LRRIQ1 | |
Cytomap | 12q21.31 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | A0A140VJN5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84125 | LRRIQ1 | RNA-P6T1-P6T1-1 | Human | Lung | MIAC | 9.93e-08 | 1.04e+00 | -0.0238 |
84125 | LRRIQ1 | RNA-P6T1-P6T1-2 | Human | Lung | MIAC | 3.39e-12 | 1.21e+00 | -0.0186 |
84125 | LRRIQ1 | RNA-P6T1-P6T1-3 | Human | Lung | MIAC | 2.21e-10 | 1.22e+00 | -0.0296 |
84125 | LRRIQ1 | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 2.95e-10 | 1.04e+00 | -0.0263 |
84125 | LRRIQ1 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.74e-03 | 3.98e-01 | -0.0822 |
84125 | LRRIQ1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 4.67e-04 | 3.88e-01 | -0.0809 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Liver | Cyst | ![]() |
Lung | IAC | ![]() |
Lung | AIS | ![]() |
Lung | AAH | ![]() |
Lung | MIAC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRRIQ1 | SNV | Missense_Mutation | rs758263387 | c.3814N>C | p.Ser1272Pro | p.S1272P | Q96JM4 | protein_coding | tolerated(0.14) | benign(0.007) | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
LRRIQ1 | SNV | Missense_Mutation | c.1093N>A | p.Glu365Lys | p.E365K | Q96JM4 | protein_coding | deleterious(0) | possibly_damaging(0.78) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
LRRIQ1 | SNV | Missense_Mutation | rs758263387 | c.3814N>C | p.Ser1272Pro | p.S1272P | Q96JM4 | protein_coding | tolerated(0.14) | benign(0.007) | TCGA-A2-A0YI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Femara | SD |
LRRIQ1 | SNV | Missense_Mutation | novel | c.3898N>A | p.Glu1300Lys | p.E1300K | Q96JM4 | protein_coding | tolerated(0.12) | benign(0.021) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LRRIQ1 | SNV | Missense_Mutation | rs758263387 | c.3814N>C | p.Ser1272Pro | p.S1272P | Q96JM4 | protein_coding | tolerated(0.14) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LRRIQ1 | SNV | Missense_Mutation | novel | c.2413N>T | p.Asp805Tyr | p.D805Y | Q96JM4 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LRRIQ1 | SNV | Missense_Mutation | c.3443C>T | p.Ser1148Leu | p.S1148L | Q96JM4 | protein_coding | deleterious(0.04) | benign(0.007) | TCGA-AO-A1KS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
LRRIQ1 | SNV | Missense_Mutation | rs758263387 | c.3814N>C | p.Ser1272Pro | p.S1272P | Q96JM4 | protein_coding | tolerated(0.14) | benign(0.007) | TCGA-AR-A0TP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
LRRIQ1 | SNV | Missense_Mutation | c.4309N>A | p.Glu1437Lys | p.E1437K | Q96JM4 | protein_coding | tolerated(0.09) | benign(0.014) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD | |
LRRIQ1 | SNV | Missense_Mutation | rs777149304 | c.1285N>A | p.Glu429Lys | p.E429K | Q96JM4 | protein_coding | tolerated(0.15) | benign(0.006) | TCGA-BH-A0B0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |